Details of the Drug
General Information of Drug (ID: DMPQBN0)
Drug Name |
Heptyl-Beta-D-Glucopyranoside
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
78617-12-6; HEPTYL-BETA-D-GLUCOPYRANOSIDE; Heptyl beta-D-glucopyranoside; (2R,3R,4S,5S,6R)-2-(Heptyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Heptyl-b-D-glucopyranoside; Heptyl b-D-glucopyranoside; B7G; n-Heptyl-I(2)-D-glucopyranoside; AC1L9LOI; heptyl-; n-Heptyl-ss-D-glucopyranosid; SCHEMBL333088; MolPort-003-935-703; C13H26O6; ZINC48016017; MFCD00063299; GC5331; AKOS027251086; DB03338; API0002901; AK187162; W0562; FT-0626931; n-Heptyl beta-D-glucopyranoside, ~98% (GC); A-7798; n-Heptyl beta-D-gluc
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 278.34 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||